Surface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxel

Surface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxel

Surface-modification of nanoparticles with PEG to confer stealth properties has been considered the most common practice for many years. However, controversial and serious challenges related to PEGylation have been identified, including lack of functionality, hindered cellular interaction, allergic...

Full description

Bibliographic Details
Published:
Online Access:http://hdl.handle.net/2047/D20292338
id ndltd-NEU--neu-cj82sr819
record_format oai_dc
spelling ndltd-NEU--neu-cj82sr8192021-04-14T05:26:22ZSurface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxelSurface-modification of nanoparticles with PEG to confer stealth properties has been considered the most common practice for many years. However, controversial and serious challenges related to PEGylation have been identified, including lack of functionality, hindered cellular interaction, allergic reactions, and stimulation of IgM production after repetitive dosing that accelerates blood clearance of nanoparticles. The development of alternative nanoparticle modifications has been encouraged to overcome these obstacles and improve therapeutic outcomes.http://hdl.handle.net/2047/D20292338
collection NDLTD
sources NDLTD
description Surface-modification of nanoparticles with PEG to confer stealth properties has been considered the most common practice for many years. However, controversial and serious challenges related to PEGylation have been identified, including lack of functionality, hindered cellular interaction, allergic reactions, and stimulation of IgM production after repetitive dosing that accelerates blood clearance of nanoparticles. The development of alternative nanoparticle modifications has been encouraged to overcome these obstacles and improve therapeutic outcomes.
title Surface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxel
spellingShingle Surface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxel
title_short Surface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxel
title_full Surface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxel
title_fullStr Surface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxel
title_full_unstemmed Surface engineered PEI-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of siRNA and paclitaxel
title_sort surface engineered pei-modified liposomes for combination treatment of drug-resistant cancers by co-delivery of sirna and paclitaxel
publishDate
url http://hdl.handle.net/2047/D20292338
_version_ 1719395949860618240

Similar Items